Email Notification
Receive Daily Availability Emails
Sign Up| Pack NDC# | Product | Strength | Supplied As | Shelf Pack | Inventory |
|---|---|---|---|---|---|
Pack NDC#
0517-6710-10
|
10% Calcium Chloride Injection, USP |
1 Gram (100 mg/mL) |
10 mL |
10 | In Stock |
Pack NDC#
0517-7604-25
|
Acetylcysteine Solution, USP |
20% |
4 mL vial |
25 | Limited Availability |
Pack NDC#
0517-7504-25
|
Acetylcysteine Solution, USP |
10% |
4 mL vial |
25 | In Stock |
Pack NDC#
0517-9120-25
|
Aminocaproic Acid Injection, USP |
250 mg/mL |
20 mL |
25 | In Stock |
Pack NDC#
0517-9191-25
|
Aminocaproic Acid Injection, USP |
250 mg/mL |
20 mL |
25 | In Stock |
Pack NDC#
0517-0401-25
|
Atropine Sulfate Injection, USP† †Drug is Not FDA Approved |
0.4 mg/mL |
1 mL |
25 | In Stock |
Pack NDC#
0517-1010-25
|
Atropine Sulfate Injection, USP† †Drug is Not FDA Approved |
1 mg/mL |
1 mL |
25 | In Stock |
Pack NDC#
0517-0720-01
|
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP |
6 mg/mL |
5 mL |
1 | In Stock |
Pack NDC#
0517-0791-01
|
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP |
6 mg/mL |
5 mL |
1 | Out of Stock |
Pack NDC#
0517-0799-01
|
Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP |
6 mg/mL |
5 mL |
1 | In Stock |
Pack NDC#
0517-2502-10
|
Caffeine and Sodium Benzoate Injection, USP† †Drug is Not FDA Approved |
250 mg/mL |
2 mL |
10 | In Stock |
Pack NDC#
0517-1820-01
|
Chlorothiazide Sodium For Injection, USP |
500 mg |
Single Dose Vial |
1 | In Stock |
Pack NDC#
0517-0031-25
|
Cyanocobalamin (B12) Injection, USP |
1000 mcg/mL |
1 mL |
25 | In Stock |
Pack NDC#
0517-0130-01
|
Cyanocobalamin (B12) Injection, USP |
1000 mcg/mL |
30 mL |
1 | In Stock |
Pack NDC#
0517-0032-25
|
Cyanocobalamin (B12) Injection, USP |
1000 mcg/mL |
10 mL |
25 | In Stock |
Pack NDC#
0517-1980-05
|
Dicyclomine Hydrochloride Injection, USP |
20 mg/2 mL |
2 mL |
5 | In Stock |
Pack NDC#
0517-9702-25
|
Droperidol Injection, USP |
5 mg/2 mL |
2 mL |
25 | Limited Availability |
Pack NDC#
0517-0420-01
|
Estradiol Valerate Injection, USP |
20 mg/mL |
5 mL |
1 | In Stock |
Pack NDC#
0517-0440-01
|
Estradiol Valerate Injection, USP |
40 mg/mL |
5 mL |
1 | In Stock |
Pack NDC#
0517-0710-01
|
Fomepizole Injection |
1 g/mL |
1.5 mL |
1 | In Stock |
Pack NDC#
0517-4605-25
|
Glycopyrrolate Injection, USP |
0.2 mg/mL |
5 mL |
25 | In Stock |
Pack NDC#
0517-4620-25
|
Glycopyrrolate Injection, USP |
0.2 mg/mL |
20 mL |
25 | In Stock |
Pack NDC#
0517-4601-25
|
Glycopyrrolate Injection, USP |
0.2 mg/mL |
1 mL |
25 | In Stock |
Pack NDC#
0517-4602-25
|
Glycopyrrolate Injection, USP |
0.2 mg/mL |
2 mL |
25 | In Stock |
Pack NDC#
0517-0901-25
|
HydrALAZINE Hydrochloride Injection, USP |
20 mg/mL |
1 mL Single Dose Vial |
25 | In Stock |
Pack NDC#
0517-1767-01
|
Hydroxyprogesterone Caproate Injection, USP |
250 mg/mL |
1 mL |
1 | In Stock |
Pack NDC#
0517-1791-01
|
Hydroxyprogesterone Caproate Injection, USP |
250 mg/mL |
1 mL |
1 | In Stock |
Pack NDC#
0517-4201-25
|
Hydroxyzine HCl Injection, USP |
25 mg/mL |
1 mL |
25 | In Stock |
Pack NDC#
0517-5602-25
|
Hydroxyzine HCl Injection, USP |
50 mg/mL |
2 mL |
25 | In Stock |
Pack NDC#
0517-5601-25
|
Hydroxyzine HCl Injection, USP |
50 mg/mL |
1 mL |
25 | In Stock |
Pack NDC#
0517-0375-05
|
Indigo Carmine Injection (Indigotindisulfonate Sodium Injection, USP)† †Drug is Not FDA Approved |
0.8% Solution |
5 mL Ampule |
5 | Limited Availability |
Pack NDC#
0517-1825-10
|
Methocarbamol Injection, USP |
100 mg/mL |
10 mL |
10 | In Stock |
Pack NDC#
0517-0740-20
|
Methylergonovine Maleate Injection, USP |
0.2 mg/mL |
1 mL |
20 | In Stock |
Pack NDC#
0517-9302-25
|
Multrys™ (trace elements injection 4*, USP)
*Each mL contains zinc 1,000 mcg, copper 60 mcg, |
* |
1 mL |
25 | Limited Availability |
Pack NDC#
0517-0735-10
|
niCARdipine Hydrochloride Injection, USP |
2.5 mg/mL |
10 mL |
10 | In Stock |
Pack NDC#
0517-4810-25
|
Nitroglycerin Injection, USP |
5 mg/mL |
10 mL |
25 | In Stock |
Pack NDC#
0517-0955-01
|
Olanzapine For Injection |
10 mg/Vial |
Single Use Vial |
1 | Limited Availability |
Pack NDC#
0517-4002-25
|
Papaverine HCl Injection, USP† †Drug is Not FDA Approved |
30 mg/mL |
2 mL |
25 | In Stock |
Pack NDC#
0517-0374-05
|
ProvayBlue® (methylene blue) Injection, 0.5%, USP |
5 mg/mL |
10 mL |
5 | In Stock |
Pack NDC#
0517-6560-05
|
Selenious Acid Injection, USP |
600 mcg/10 mL |
10 mL |
5 | In Stock |
Pack NDC#
0517-6502-10
|
Selenious Acid Injection, USP |
12 mcg/2 mL |
2 mL |
10 | Coming Soon |
Pack NDC#
0517-9305-25
|
Tralement® (trace elements injection 4*, USP)
*Each mL contains zinc 3 mg, copper 0.3 mg, |
* |
1 mL |
25 | Out of Stock |
Pack NDC#
0517-0960-10
|
Tranexamic Acid Injection |
100 mg/mL |
10 mL |
10 | Out of Stock |
Pack NDC#
0517-2310-05
|
Venofer® iron sucrose injection, USP |
200 mg/10 mL |
10 mL |
5 | In Stock |
Pack NDC#
0517-2325-10
|
Venofer® iron sucrose injection, USP |
50 mg/2.5 mL |
2.5 mL |
10 | In Stock |
Pack NDC#
0517-2340-10
|
Venofer® iron sucrose injection, USP |
100 mg/5 mL |
5 mL |
10 | In Stock |
Pack NDC#
0517-2340-25
|
Venofer® iron sucrose injection, USP |
100 mg/5 mL |
5 mL |
25 | In Stock |
Pack NDC#
0517-6103-25
|
Zinc Sulfate Injection, USP |
3 mg/mL |
10 mL |
25 | In Stock |
Pack NDC#
0517-8005-25
|
Zinc Sulfate Injection, USP |
5 mg/mL |
5 mL |
25 | In Stock |
Pack NDC#
0517-6101-25
|
Zinc Sulfate Injection, USP |
1 mg/mL |
10 mL |
25 | In Stock |
FIND OUT FIRST
Receive daily availability emails
News Center
American Regent Launches Multrys™ (trace elements injection 4*, USP)
Melville, NY – September 2, 2021: American Regent, Inc. introduces FDA-approved Multrys™ (trace elements injection 4*, USP). Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
For patients as young as one year of age who have intolerance to, or have had an unsatisfactory response to, oral iron, Injectafer may now be administered for IDA treatment1
Basking Ridge, N.J. and Shirley, N.Y. (December 15, 2021) – Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.
St. John’s University and American Regent Post-Doctoral Pharmaceutical Industry Fellowship
The program offers fellowships in both Medical Affairs & Pharmaceutical Marketing and in Clinical Research & Development.